Hormonal Kontrasepsiyonda Güncel Yaklaşımlar
Özet
Referanslar
Centers for Disease Control and Prevention. (2024). U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recommendations and Reports, 73(4), 1–126. https://www.cdc.gov/mmwr/volumes/73/rr/rr7304a1.htm
World Health Organization. (2015). Medical eligibility criteria for contraceptive use (5th ed.; WHO/RHR/15.07). https://www.afro.who.int/sites/default/files/2017-06/WHO_RHR_15.07_eng.pdf
Nguyen, A. T., Curtis, K. M., Tepper, N. K., Kortsmit, K., Brittain, A. W., Snyder, E. M., Cohen, M. A., Zapata, L. B., Whiteman, M. K., & diğerleri. (2024). U.S. medical eligibility criteria for contraceptive use, 2024 (MMWR Recommendations and Reports, 73[No. RR-4], 1–126).
World Health Organization, & Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs. (2022). Family planning: A global handbook for providers (4th ed.). World Health Organization. Family planning: a global handbook for providers, 4th ed
The American College of Obstetricians and Gynecologists. (2017). Long-acting reversible contraception: Implants and intrauterine devices (Practice Bulletin No. 186). Obstetrics & Gynecology, 130(5), e251–e269. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/11/long-acting-reversible-contraception-implants-and-intrauterine-devices
Faculty of Sexual & Reproductive Healthcare. (2023). FSRH guideline: Progestogen-only pills (BMJ Sexual & Reproductive Health, 48 Suppl 1, 1). BMJ Group. https://srh.bmj.com/content/48/Suppl_1/1.abstract
American College of Obstetricians and Gynecologists’ Committee on Clinical Consensus–Gynecology. (2022). General approaches to medical management of menstrual suppression (ACOG Clinical Consensus No. 3). Obstetrics & Gynecology, 140(3), e95–e111. https://doi.org/10.1097/AOG.0000000000004899
Referanslar
Centers for Disease Control and Prevention. (2024). U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recommendations and Reports, 73(4), 1–126. https://www.cdc.gov/mmwr/volumes/73/rr/rr7304a1.htm
World Health Organization. (2015). Medical eligibility criteria for contraceptive use (5th ed.; WHO/RHR/15.07). https://www.afro.who.int/sites/default/files/2017-06/WHO_RHR_15.07_eng.pdf
Nguyen, A. T., Curtis, K. M., Tepper, N. K., Kortsmit, K., Brittain, A. W., Snyder, E. M., Cohen, M. A., Zapata, L. B., Whiteman, M. K., & diğerleri. (2024). U.S. medical eligibility criteria for contraceptive use, 2024 (MMWR Recommendations and Reports, 73[No. RR-4], 1–126).
World Health Organization, & Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs. (2022). Family planning: A global handbook for providers (4th ed.). World Health Organization. Family planning: a global handbook for providers, 4th ed
The American College of Obstetricians and Gynecologists. (2017). Long-acting reversible contraception: Implants and intrauterine devices (Practice Bulletin No. 186). Obstetrics & Gynecology, 130(5), e251–e269. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/11/long-acting-reversible-contraception-implants-and-intrauterine-devices
Faculty of Sexual & Reproductive Healthcare. (2023). FSRH guideline: Progestogen-only pills (BMJ Sexual & Reproductive Health, 48 Suppl 1, 1). BMJ Group. https://srh.bmj.com/content/48/Suppl_1/1.abstract
American College of Obstetricians and Gynecologists’ Committee on Clinical Consensus–Gynecology. (2022). General approaches to medical management of menstrual suppression (ACOG Clinical Consensus No. 3). Obstetrics & Gynecology, 140(3), e95–e111. https://doi.org/10.1097/AOG.0000000000004899
